Everlum Bio focuses on addressing rare diseases through a personalized and expedited approach to treatment. The company employs a multi-modality strategy, utilizing various therapeutic methods such as gene therapy, antisense oligonucleotides (ASOs), and small molecules. By leveraging a proprietary AI platform and collaborating with leading scientists, Everlum Bio develops tailored cure plans that prioritize the specific needs of each patient. This innovative approach aims to streamline the drug discovery process, allowing for rapid proof of concept and the potential for immediate access to customized treatment options.

The company also utilizes induced pluripotent stem cells (iPSCs) to enhance drug discovery, enabling researchers to screen potential drug candidates effectively. By studying patient-derived cells, Everlum Bio can identify key disease targets and pathways, which informs the development of novel therapeutics. While animal models are currently a necessary part of the FDA approval process, Everlum Bio is committed to advancing towards a future where such models are no longer required. Their dedication to transparency and patient-centric care is evident in their mission to provide families with a clear path to treatment, ultimately aiming to eliminate rare diseases by 2035.

United States

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service".  We are relentlessly focused on innovating the drug development process.  Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

Everlum Bio

Company Details